Injectable Platelet Rich Fibrin With Collagen Matrix in Treatment of Multiple Gingival Recession.

Sponsor
University of Baghdad (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05389059
Collaborator
(none)
20
1
2
16.2
1.2

Study Details

Study Description

Brief Summary

This study is proposing the use of i-PRF clot as a scaffold for the XCM in order to obtain a novel biomaterial, incorporating active growth factors and collagen matrix in a single framework, based on the potential effect of i-PRF to enhance fibroblast activity and angiogenesis stimulation for treatment of multiple gingival recession.

Condition or Disease Intervention/Treatment Phase
  • Procedure: CAF+CM
  • Procedure: I-PRF
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Value of Injectable Platelet Rich Fibrin With Volume Stable Collagen Matrix in Treatment of Multiple Gingival Recession; a Randomized Clinical Trial.
Actual Study Start Date :
Apr 25, 2022
Anticipated Primary Completion Date :
Mar 30, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: Control arm

Patients with Gingival recessions are type 1 recession RT1 (cairo et al,2011) which correspond to Miller I&II gingival recession.

Procedure: CAF+CM
Periodontal surgery including CAF+CM application

Other: Experimental arm

Patients with Gingival recessions are type 1 recession RT1 (cairo et al,2011) which correspond to Miller I&II gingival recession.

Procedure: CAF+CM
Periodontal surgery including CAF+CM application

Procedure: I-PRF
Periodontal surgery including CAF+CM application with i-PRF

Outcome Measures

Primary Outcome Measures

  1. Reduction in gingival recession depth on the buccal sides of type one gingival recessionRT1 [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]

    The primary outcome of the study is the reduction in gingival recession depth on the buccal sides of RT1 gingival recession, between the baseline preoperative measurement and follow-up at 3 months and 6 months. The Recession Depth (RD) is Measured in millimeter (mm) from CEJ (Cemento-Enamel-Junction) to the gingival margin using UNC-15 probe.

Secondary Outcome Measures

  1. Improvement in Gingival Thickness (GT) [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]

    Gingival Thickness (GT) is determined at 1.5 mm apical to the gingival margin using a caliper (endodontic reamer#20) rounded to the nearest 0.1mm.

  2. Improvement in the Keratinized Tissue Height (KTH) [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]

    Keratinized Tissue Height (KTH) is measured in millimeters (mm) taken at the mid buccal aspect of the involved teeth from the gingival margin to the muco-gingival junction, by a manual periodontal probe (UNC-15 probe,Hu-Friedy,Chicago,USA).

  3. Reduction in the Recession Width (RW) [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]

    Recession Width (RW) is measured in millimeter (mm) at the Cement-Enamel Junction (CEJ) using UNC-15 probe.

  4. Reduction in Probing Pocket Depth (PPD) [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]

    Probing Pocket Depth (PPD) is measured in millimeter (mm) from the gingival margin to the apical extend of the probe.

  5. Reduction Clinical Attachment Level (CAL) [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]

    Clinical Attachment Level (CAL) is measured in millimeter (mm) from the CEJ to the apical extend of the probe.

  6. Measuring Plaque-Index (PI) [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]

    Plaque-Index (PI) is measured as a percentage of the presence of Plaque on four surfaces of the teeth using a manual periodontal probe.

  7. Measuring Bleeding On Probing (BOP) [Between the baseline preoperative measurement and follow-up at 3 months and 6 months]

    Bleeding On Probing (BOP) is measured as a percentage of sites with bleeding on probing using a manual periodontal probe.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Presence of at least two localized gingival recessions on either sides of the maxilla and/or mandible excluding molar region.

  • The cemento-enamel junction (CEJ) is visible in the teeth for root coverage procedures.

  • All recessions are type 1recession RT1 (cairo et al,2011) which correspond to Miller I&II gingival recession

  • All patients must demonstrate adequate plaque control with a fullmouth plaque score less than 20% and with .

  • All patients at least 18 years of age and of both genders.

Exclusion Criteria:
  • Smoker Patients .

  • Patients with diabetes.

  • Patients with a history of malignancy, radiotherapy, or chemotherapy for malignancy.

  • pregnant or nursing women.

  • Patients taking medications or having treatments with an effect on mucosal healing in general (e.g. steroids, large doses of antiinflammatory drugs).

  • Patients with a disease affecting connective tissue metabolism.

  • Patients allergic to collagen.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Baghdad / College of Dentistry Baghdad Iraq 10047

Sponsors and Collaborators

  • University of Baghdad

Investigators

  • Principal Investigator: Basima Gh Ali, MSc, University of Baghdad / College of Dentistry
  • Study Director: Thair AL Hassan, PHD, University of Baghdad / College of Dentistry

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Basima Ghaffoori Ali, PHD student, University of Baghdad
ClinicalTrials.gov Identifier:
NCT05389059
Other Study ID Numbers:
  • 519622
First Posted:
May 24, 2022
Last Update Posted:
May 24, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Basima Ghaffoori Ali, PHD student, University of Baghdad
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 24, 2022